LT3474850T - Intranazalinė kompozicija, apimanti betahistiną - Google Patents

Intranazalinė kompozicija, apimanti betahistiną

Info

Publication number
LT3474850T
LT3474850T LTEP18703749.4T LT18703749T LT3474850T LT 3474850 T LT3474850 T LT 3474850T LT 18703749 T LT18703749 T LT 18703749T LT 3474850 T LT3474850 T LT 3474850T
Authority
LT
Lithuania
Prior art keywords
betahistine
intranasal composition
intranasal
composition
Prior art date
Application number
LTEP18703749.4T
Other languages
English (en)
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of LT3474850T publication Critical patent/LT3474850T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
LTEP18703749.4T 2017-02-02 2018-02-02 Intranazalinė kompozicija, apimanti betahistiną LT3474850T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine

Publications (1)

Publication Number Publication Date
LT3474850T true LT3474850T (lt) 2020-08-10

Family

ID=61187302

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18703749.4T LT3474850T (lt) 2017-02-02 2018-02-02 Intranazalinė kompozicija, apimanti betahistiną
LTEP20170448.3T LT3698791T (lt) 2017-02-02 2018-02-02 Intranazalinė kompozicija, apimanti betahistiną

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP20170448.3T LT3698791T (lt) 2017-02-02 2018-02-02 Intranazalinė kompozicija, apimanti betahistiną

Country Status (33)

Country Link
US (2) US10456386B2 (lt)
EP (2) EP3474850B1 (lt)
JP (3) JP2020506930A (lt)
CN (1) CN110418643A (lt)
AR (1) AR111699A1 (lt)
AU (1) AU2018216970B2 (lt)
BR (1) BR112019015687A2 (lt)
CA (1) CA3051725A1 (lt)
CL (1) CL2019002145A1 (lt)
CO (1) CO2019008657A2 (lt)
DK (2) DK3474850T3 (lt)
EA (1) EA201991817A1 (lt)
ES (1) ES2807798T3 (lt)
FI (1) FI3698791T3 (lt)
HR (2) HRP20231706T1 (lt)
HU (1) HUE050829T2 (lt)
IL (1) IL268353B2 (lt)
LT (2) LT3474850T (lt)
MA (1) MA46778B1 (lt)
MX (1) MX2019008961A (lt)
MY (1) MY196333A (lt)
NZ (1) NZ755931A (lt)
PH (1) PH12019501785A1 (lt)
PL (1) PL3474850T3 (lt)
PT (2) PT3698791T (lt)
RS (2) RS60554B1 (lt)
SA (1) SA519402324B1 (lt)
SG (1) SG11201906980YA (lt)
SI (1) SI3474850T1 (lt)
TN (1) TN2019000220A1 (lt)
TW (1) TWI760429B (lt)
WO (1) WO2018141922A1 (lt)
ZA (1) ZA201904955B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
CA3179806A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (lt) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
PT1530965E (pt) 2003-11-11 2006-05-31 Udo Mattern Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
JP2007533733A (ja) 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド 食物摂取管理の方法
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8119668B2 (en) * 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
CA2710271A1 (en) * 2007-12-21 2009-07-09 Schering-Plough Healthcare Products, Inc. Enhancing photostabilization of oxymetazoline
EP2278999A4 (en) * 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
WO2009143572A1 (en) * 2008-05-27 2009-12-03 The University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
EP3200828B1 (en) * 2014-10-03 2020-08-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
EP3698791A1 (en) 2020-08-26
EP3474850B1 (en) 2020-04-22
AU2018216970B2 (en) 2023-12-21
MA46778B1 (fr) 2022-08-31
US20180214432A1 (en) 2018-08-02
JP2024019731A (ja) 2024-02-09
US10456386B2 (en) 2019-10-29
CN110418643A (zh) 2019-11-05
HRP20231706T1 (hr) 2024-03-15
ES2807798T3 (es) 2021-02-24
MA46778A1 (fr) 2021-04-30
HRP20201137T1 (hr) 2021-01-22
EP3474850A1 (en) 2019-05-01
CA3051725A1 (en) 2018-08-09
MX2019008961A (es) 2019-10-15
SA519402324B1 (ar) 2023-03-16
JP2022051872A (ja) 2022-04-01
CL2019002145A1 (es) 2019-11-04
SI3474850T1 (sl) 2020-09-30
AR111699A1 (es) 2019-08-14
PH12019501785A1 (en) 2020-07-06
AU2018216970A1 (en) 2019-08-22
BR112019015687A2 (pt) 2020-04-28
RS60554B1 (sr) 2020-08-31
RS65099B1 (sr) 2024-02-29
US20200022963A1 (en) 2020-01-23
DK3698791T3 (da) 2024-01-15
EA201991817A1 (ru) 2020-01-27
MY196333A (en) 2023-03-24
IL268353A (en) 2019-09-26
ZA201904955B (en) 2021-05-26
KR20190116341A (ko) 2019-10-14
IL268353B2 (en) 2023-10-01
JP2020506930A (ja) 2020-03-05
TN2019000220A1 (en) 2021-01-07
DK3474850T3 (da) 2020-08-03
HUE050829T2 (hu) 2021-01-28
PL3474850T3 (pl) 2020-09-21
CO2019008657A2 (es) 2020-01-17
TWI760429B (zh) 2022-04-11
SG11201906980YA (en) 2019-08-27
PT3474850T (pt) 2020-07-27
LT3698791T (lt) 2024-02-12
TW201831179A (zh) 2018-09-01
WO2018141922A1 (en) 2018-08-09
IL268353B1 (en) 2023-06-01
FI3698791T3 (fi) 2024-01-11
NZ755931A (en) 2022-07-29
EP3698791B1 (en) 2023-10-25
PT3698791T (pt) 2024-01-12

Similar Documents

Publication Publication Date Title
PL3697376T3 (pl) Kompozycja
GB201703455D0 (en) Composition
GB2562466B (en) Composition
GB201719139D0 (en) Composition
GB201700504D0 (en) Composition
GB201713636D0 (en) Composition
IL268353A (en) The intranasal composition includes betahistine
GB201712151D0 (en) Composition
GB201707238D0 (en) Composition
GB201702833D0 (en) Composition
GB201816988D0 (en) Composition
LT3576546T (lt) Probiotikų kompozicija
GB201721674D0 (en) Composition
GB201718871D0 (en) Composition
GB201715135D0 (en) Composition
GB201711446D0 (en) Composition
GB201707920D0 (en) Composition
GB201710716D0 (en) Intranasal formulations
GB201701490D0 (en) Intranasal formulations
PL3576546T3 (pl) Kompozycja probiotyczna
GB201721675D0 (en) Composition
GB201719763D0 (en) Composition
GB201719456D0 (en) Composition
GB201717637D0 (en) Composition
GB201713225D0 (en) Composition